Skip to main content

Table 2 Cost parameters input in the model

From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance

Parameters Value (range) Resource
Cabazitaxel (60 mg) 13,170.31 (10,536.248–15,804.384) RED BOOK
Abiraterone (250 mg) 95.26 (76.208–114.312) RED BOOK
Enzalutamide (40 mg) 115.486 (92.389–138.583) RED BOOK
Prednisone (10 mg) 0.53 (0.424–0.636) RED BOOK
Prednisone (5 mg) 0.39 (0.312–0.468) RED BOOK
Administration per unit CPT:96365 74.16 (59.328–88.992) CMS
Musculoskeletal pain or discomfort per event 364.8 (291.84–437.76) [26], 2015
Renal disorder per event 5966.67 (4773.336–7160.004) [27], 2015
Anemia per event 1881 (1826–1910) [27], 2015
Leukopenia per event 3066 (2758–3384) [27], 2015
Neutropenia per event 3066 (2758–3384) [27], 2015
Laboratory tests per event 76 (68–84) [27], 2015
Chest/Abdomen/Pelvis CT per event 828 (598–1083) [27], 2015
PSA per event 25 (20–30) [28], 2015
Bone scanning per event 253.46 (202.768–304.152) [28], 2015
Cost of supportive care per cycle 1213 (987–1438) [29], 2018
Routine follow-up of patients per unit 422 (348.1–495.8) [29], 2018
  1. CT Computed Tomography, PSA prostate specific antigen